Retatrutide is an investigational peptide-based compound designed to activate three metabolically relevant receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple-agonist design distinguishes it from single- and dual-receptor incretin compounds and has made it an important subject of metabolic research.

Research has examined how coordinated signalling across these receptor systems may influence appetite regulation, glucose homeostasis, lipid metabolism, energy expenditure, and body-weight regulation. GLP-1 and GIP receptors participate in incretin and metabolic signalling, while glucagon receptor activity introduces an additional pathway involved in hepatic metabolism and energy balance.

Retatrutide has progressed from preclinical investigation into an extensive human clinical research program, including studies evaluating obesity, metabolic dysfunction, and associated cardiometabolic measures. Findings to date have generated considerable research interest in how simultaneous activation of GLP-1, GIP, and glucagon pathways may differ from more selective receptor-targeting approaches.

Although its clinical research program is relatively advanced, retatrutide remains investigational. Ongoing studies continue to evaluate its efficacy, safety, tolerability, dose-response characteristics, and longer-term metabolic effects.